Drug safety alert: IPC flags adverse reactions linked to rheumatoid arthritis drug Piroxicam

Published On 2022-10-06 12:21 GMT   |   Update On 2022-10-06 12:21 GMT

The Indian Pharmacopoeia Commission (IPC), through its recently issued drug safety alert for the month of September ,has revealed that Piroxicam, a non-steroidal anti-inflammatory agent (NSAID) which is used to treat the symptoms of osteoarthritis and rheumatoid arthritis, is linked with Adverse Drug Reactions (ADRs) named Fixed Drug Eruption.This came after preliminary analysis of Adverse...

Login or Register to read the full article

The Indian Pharmacopoeia Commission (IPC), through its recently issued drug safety alert for the month of September ,has revealed that Piroxicam, a non-steroidal anti-inflammatory agent (NSAID) which is used to treat the symptoms of osteoarthritis and rheumatoid arthritis, is linked with Adverse Drug Reactions (ADRs) named Fixed Drug Eruption.

This came after preliminary analysis of Adverse Drug Reactions (ADRs) from the Pharmacovigilance Programme of India (PvPI) database.

Piroxicam is in a class of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs). Piroxicam works by reducing hormones that cause inflammation and pain in the body. Piroxicam is used to reduce the pain, inflammation, and stiffness caused by rheumatoid arthritis and osteoarthritis.

For more details, check out the link given below:

Drug Safety Alert: IPC Flags Adverse Reactions Linked To Rheumatoid Arthritis Drug Piroxicam

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News